Brainstorm Cell Therapeutics (NASDAQ:BCLI) Now Covered by Analysts at StockNews.com

Research analysts at StockNews.com started coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) in a report released on Thursday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Brainstorm Cell Therapeutics Price Performance

Shares of Brainstorm Cell Therapeutics stock opened at $1.15 on Thursday. The stock’s 50 day simple moving average is $1.62 and its 200-day simple moving average is $1.93. The stock has a market cap of $6.56 million, a P/E ratio of -0.24 and a beta of 0.75. Brainstorm Cell Therapeutics has a 1-year low of $1.05 and a 1-year high of $11.25.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last released its quarterly earnings data on Monday, April 7th. The biotechnology company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.02). As a group, research analysts expect that Brainstorm Cell Therapeutics will post -3.01 EPS for the current fiscal year.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.